

Dupilumab (DUPIXENT) in Eosinophilic Esophagitis

Criteria for Use

May 2024

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive dupilumab.

- Concurrent use of live (attenuated) vaccines or treatment with live (attenuated) vaccines within the previous 12 weeks.
- Untreated parasitic (helminth) infection.

Inclusion Criteria

All of the following must be selected to meet criteria for use.

- Diagnosis of eosinophilic esophagitis (EoE) including histologic evidence of eosinophilic inflammation (≥ 15 eosinophils / high power field) made or confirmed by a VA / VA Community Care gastroenterologist.
- Prescribed by a VA / VA Community Care gastroenterologist OR an immunologist, allergist, or other designated expert in the management of EoE in consultation with a VA / VA Community Care gastroenterologist.
- Tried a swallowed topical glucocorticoid (e.g., swallowed aerosolized fluticasone or commercially available budesonide oral suspension) for at least 8 to 12 weeks, unless it was medically inadvisable, and had an inadequate response or intolerance

Additional Inclusion Criteria

Select if applicable.

- For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy.

Other Justification

Prepared: May 2024.

Contact: Francine Goodman, PharmD, BCPS, National Program Manager, VA Pharmacy Benefits Management Services (12PBM)
